Caili Ma | Public Health | Research Excellence Award

Posted on by The Scientist

Ms. Caili Ma | Public Health | Research Excellence Award

Head-Nurse | The Second Xiangya Hospital Of Central South University | China 

Dr. Caili Ma is an emerging researcher whose scholarly contributions reflect a focused commitment to advancing evidence-based practice in clinical and nursing sciences. With 67 citations, 8 peer-reviewed publications, and an h-index of 4, Dr. Ma has steadily built a research portfolio that demonstrates both scientific rigor and growing global visibility. Her work spans critical themes in healthcare delivery, professional identity formation, patient-centered care, and stigma reduction within clinical education environments. Notably, her recent randomized controlled trial evaluating the “credit bank” intervention highlights her dedication to designing innovative, measurable strategies that enhance nursing students’ professional identity while addressing the pervasive issue of public stigma an area with significant implications for workforce development, healthcare quality, and long-term professional resilience. Dr. Ma’s collaborative footprint, illustrated by contributions involving more than 50 co-authors, underscores her engagement in interdisciplinary and multicenter research networks, enabling broader translational impact and methodological diversity. Her research influence extends beyond publications, contributing to ongoing discussions in clinical education reform and psychosocial determinants of healthcare performance. Although early in her academic trajectory, her work already demonstrates societal relevance by informing policies and practices aimed at strengthening the nursing workforce, improving mental and professional well-being among trainees, and fostering more inclusive healthcare environments. Through the combination of rigorous study design, collaborative scholarship, and commitment to addressing structural and interpersonal challenges in healthcare systems, Dr. Ma continues to shape a research agenda that aligns with international priorities in health education, stigma reduction, and sustainable professional development. Her growing citation profile and publication output reflect her expanding role in advancing high-quality research that bridges clinical education, behavioral science, and patient-oriented perspectives.

Profiles: Scopus | ORCID 

Featured Publications

  1. Qiu, C., Ni, X., Wang, Y., Cao, M., Li, X., Huang, Z., Chen, Q., Ma, C., & He, Y. (2025). Effects of a “credit bank” intervention on the professional identity and public stigma among nursing students: A randomized controlled trial. Nurse Education Today. Advance online publication. https://doi.org/10.1016/j.nedt.2025.106915     

 

Ilias Karaiskos | Public Health | Best Researcher Award

Posted on by The Scientist

Dr. Ilias Karaiskos | Public Health | Best Researcher Award

1st Department of Internal Medicine-Infectious Diseases |  Hygeia hospital, Athens | Greece

Dr. Ilias Karaiskos is a distinguished physician and clinical researcher specializing in internal medicine and infectious diseases at the 1st Department of Internal Medicine, Hygeia General Hospital, Athens, Greece. Working under the leadership of Professor H. Giamarellou, he has contributed extensively to the management of complex infections, infection control, and antimicrobial stewardship within one of Greece’s most advanced and internationally accredited healthcare institutions. Dr. Karaiskos’s research focuses on antimicrobial pharmacokinetics, multidrug-resistant pathogens, and optimized antibiotic therapy in critically ill patients. His doctoral work on the pharmacokinetics of colistin significantly influenced global clinical practice, forming part of the International Consensus Guidelines for the Optimal Use of Polymyxins. Recognized by the Hellenic Society for Infectious Diseases with the Best PhD Award (2015), his research has shaped antibiotic dosing strategies that improve patient outcomes and reduce antimicrobial resistance. With over 80 peer-reviewed publications and an h-index of 39, Dr. Karaiskos has amassed more than 5,600 citations through collaborative studies with leading European and global research consortia, including the EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). His recent works address the efficacy of novel β-lactamase inhibitors, pharmacokinetics of ceftazidime-avibactam in renal replacement therapy, and strategies for infection control in intensive care settings. Through his clinical leadership, academic collaborations, and evidence-based research, Dr. Karaiskos continues to advance the global fight against antimicrobial resistance, shaping policies and treatment guidelines that enhance the quality and safety of infectious disease management worldwide.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate

Featured Publications

  1. Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Karaiskos, I., … (2019). International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and others. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 39(1), 10–39. Citations: 949

  2. Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Karaiskos, I., … (2009). Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrobial Agents and Chemotherapy, 53(8), 3430–3436. Citations: 637

  3. Gutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hsueh, P. R., Viale, P., Karaiskos, I., … (2017). Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. The Lancet Infectious Diseases, 17(7), 726–734. Citations: 545

  4. Karaiskos, I., & Giamarellou, H. (2014). Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: Current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy, 15(10), 1351–1370. Citations: 435

  5. Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019). The “old” and the “new” antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Frontiers in Public Health, 7, 151. Citations: 328